Pacs Group Inc

Análisis de la acción Pacs Group Inc (PACS)

$47.500

+0.751 (+1.58%)Al cierre

Loading chart…
Máximo
47.710
Apertura
46.620
Precio medio ponderado por volumen
47.07
Volumen
667.17K
Capitalización
—
Mínimo
46.000
Importe
31.40M
EV/EBITDA, TTM
18.42

PACS Group, Inc. is a holding company. The Company, through its subsidiaries, is engaged in providing various skilled nursing facilities (SNF) and assisted living facilities (ALF) services. It provides senior care, assisted living, and independent living options in its communities. It operates 321 post-acute care facilities across 17 states serving over 31,700 patients daily. Its post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after they have been discharged from the hospital. This ecosystem ranges from higher acuity, higher-cost settings, such as long-term acute care hospitals and inpatient rehabilitation facilities, to lower acuity, lower-cost settings, such as assisted living facilities, and home health. The Company also provides independently operated facilities with technology, support, and back-office services.

pacs.com

Análisis de IA of Pacs Group Inc (PACS)

Comprar

Pacs Group Inc is a good buy right now due to its strong recent performance and positive financial outlook. The current price is $46.91, with a forward P/E of 15.528, indicating potential for growth compared to its earnings. Additionally, the company reported a significant year-over-year revenue increase of 9.1% in Q2 2026, reaching $1.43 billion, and raised its full-year revenue guidance to between $5.75 billion and $5.85 billion. The main risk is the RSI of 74.549, suggesting the stock may be overbought in the short term, but the overall fundamentals and analyst sentiment support a buy.

Métricas de valoración

El PER previsto actual de Pacs Group Inc (PACS) es 15.53, frente a su media de 5 años de 12.96.

PER previsto

Valor razonable
Media 5A P/E
12.96
P/E actual
15.53
Sobrevalorada
18.88
Infravalorada
7.03

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
6.42
EV/EBITDA actual
18.42
Sobrevalorada
32.99
Infravalorada
-20.15

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.83
P/S actual
1.13
Sobrevalorada
1.18
Infravalorada
0.47

Ballenas con PACS en cartera

C

Cohen & Steers Capital Management, Inc.

+ Con en carteraPACS

-4.91%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-05 (ET)

05:30:00

Omega Healthcare Transfers 32 Nursing Facilities in Florida, Rent Increases by $26.1M

2026-09-21 (ET)

16:30:00

PACS Group Chief Legal Officer John Mitchell Retires, Patrick J. Murphy to Succeed

2026-09-01 (ET)

16:30:00

Pacs Group Acquires 32 Skilled Nursing Facilities in Florida

2026-08-04 (ET)

17:00:00

Company Raises 2026 Revenue Outlook to $5.75B-$5.85B

17:00:00

Company Reports Q2 Revenue of $1.43B, Exceeding Expectations

Noticias

Preguntas frecuentes sobre PACS, respondidas por Alphio AI

PACS Group, Inc. is a holding company. The Company, through its subsidiaries, is engaged in providing various skilled nursing facilities (SNF) and assisted living facilities (ALF) services. It provides senior care, assisted living, and independent living options in its communities. It operates 321 post-acute care facilities across 17 states serving over 31,700 patients daily. Its post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after they have been discharged from the hospital. This ecosystem ranges from higher acuity, higher-cost settings, such as long-term acute care hospitals and inpatient rehabilitation facilities, to lower acuity, lower-cost settings, such as assisted living facilities, and home health. The Company also provides independently operated facilities with technology, support, and back-office services. It operates in the Healthcare sector.

Pacs Group Inc is a good buy right now due to its strong recent performance and positive financial outlook. The current price is $46.91, with a forward P/E of 15.528, indicating potential for growth compared to its earnings. Additionally, the company reported a significant year-over-year revenue increase of 9.1% in Q2 2026, reaching $1.43 billion, and raised its full-year revenue guidance to between $5.75 billion and $5.85 billion. The main risk is the RSI of 74.549, suggesting the stock may be overbought in the short term, but the overall fundamentals and analyst sentiment support a buy.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar